A phase 0 single dose study to evaluate the pharmacokinetics/-dynamics and specific targeting properties of 124-I-F8IL10 in patients with active rheumatoid arthritis.

Trial Profile

A phase 0 single dose study to evaluate the pharmacokinetics/-dynamics and specific targeting properties of 124-I-F8IL10 in patients with active rheumatoid arthritis.

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 22 May 2013

At a glance

  • Drugs F8 IL10 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top